NewAmsterdam Pharma Co N.V. financial data

Symbol
NAMS, NAMSW on Nasdaq
Location
Gooimeer 2 35, Narrden, Netherlands
State of incorporation
Netherlands
Fiscal year end
December 31
Former names
NewAmsterdam Pharma Co B.V. (to 11/22/2022)
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 90M shares
Common Stock, Shares, Outstanding 90M shares
Entity Public Float 577M USD
Common Stock, Value, Issued 11.2M USD
Weighted Average Number of Shares Outstanding, Basic 94.7M shares +15.4%
Weighted Average Number of Shares Outstanding, Diluted 94.7M shares +15.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.28M USD +32.7%
Research and Development Expense 38.4M USD +11.8%
Operating Income (Loss) -52.6M USD -23.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -39M USD -1.87%
Net Income (Loss) Attributable to Parent -39M USD -1.87%
Earnings Per Share, Basic -0.41 USD/shares +12.8%
Earnings Per Share, Diluted -0.41 USD/shares +12.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 445M USD
Property, Plant and Equipment, Net 234K USD
Operating Lease, Right-of-Use Asset 554K USD
Assets 447M USD
Accounts Payable, Current 5.28M USD
Liabilities, Current 45.3M USD
Operating Lease, Liability, Noncurrent 328K USD
Liabilities 59.3M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 4.42M USD
Retained Earnings (Accumulated Deficit) -450M USD
Stockholders' Equity Attributable to Parent 387M USD +3.78%
Liabilities and Equity 447M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -54.6M USD -71.4%
Net Cash Provided by (Used in) Financing Activities 198M USD +8185%
Net Cash Provided by (Used in) Investing Activities -385K USD -5400%
Common Stock, Shares Authorized 400M shares
Common Stock, Shares, Issued 90M shares
Common Stock, Par or Stated Value Per Share 0.12 EUR/shares
Deferred Tax Assets, Valuation Allowance 130M USD +59.6%
Deferred Tax Assets, Gross 130M USD +59.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -39M USD -1.87%
Operating Lease, Liability, Current 234K USD
Deferred Tax Assets, Operating Loss Carryforwards 75.7M USD +31%
Unrecognized Tax Benefits 0 USD
Depreciation, Depletion and Amortization 15K USD +66.7%
Deferred Tax Assets, Net of Valuation Allowance 12K USD -55.6%
Share-based Payment Arrangement, Expense 8.29M USD +49.2%